Menu

Cancer

Pivotal Phase II study showed nearly 80 percent of people with hard-to-treat type of chronic lymphocytic leukaemia responded to investigational medicine venetoclax

, , , ,

Regulatory applications for venetoclax have been submitted to the U.S. Food and Drug Administration and European Medicines Agency Additional results in previously treated chronic lymphocytic leukaemia from a separate Phase Ib study published online today in New England Journal of Medicine Basel, 7 December 2015 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new, […]

GE Healthcare Announces Omnyx™ Digital Pathology Collaboration with Caradigm

, , ,

GE Healthcare to offer Caradigm’s Identity and Access Management suite with Omnyx digital pathology solutions to streamline pathology workflows. PITTSBURGH, PA – November 19, 2014 – GE Healthcare, a leader in technology innovation, today announced it will resell Caradigm’s Single Sign-On and Context Management solutions in the United States, Canada, and specific EU countries to […]

Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma

, , , ,

KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH, November 16, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 […]

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time

, , ,

By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J., November 6, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the […]

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014

,

Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company’s Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company’s oncology and […]

Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

, ,

October 27, 2014 – WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma […]

GE Healthcare and Karolinska University Hospital in Sweden Partner to Improve the Treatment of Pelvic Cancer

,

The new care pathway for advanced pelvic cancer encourages knowledge transfer and multidisciplinary care Stockholm, Sweden – 17 October 2014 – GE Healthcare and Karolinska University Hospital in Stockholm, Sweden, have established a partnership to improve the efficiency of the care pathway for pelvic cancer patients and reduce unwarranted clinical variation. GE Healthcare will be […]

Allegheny Health Network First to Install SenoClaire, New Breast Imaging with 3D Tomosynthesis Solution

, ,

Allegheny, PA, October 1, 2014 — Allegheny Health Network is the first center in the nation to install SenoClaire*, GE Healthcare’s (NYSE: GE) new breast tomosynthesis solution designed with a three-dimensional imaging technology. SenoClaire, which was approved by the FDA earlier this month, uses a low-dose short X-ray sweep around the positioned breast with nine […]

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing

, ,

Aliso Viejo, CA – September 30, 2014 – GE Healthcare today announced an agreement between its affiliate, Clarient Diagnostic Services, Inc. (Clarient) and GlaxoSmithKline (GSK). The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types. The collaboration […]

Roche’s Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy

, , ,

Final data from Phase III CLEOPATRA study showed people with previously untreated HER2-positive metastatic breast cancer who received Perjeta, Herceptin and docetaxel chemotherapy lived a median of 56.5 months compared to 40.8 months for people who received Herceptin and chemotherapy1 Median overall survival of almost five years is the longest observed to date in people […]

1 2 3 4›»